Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OSE Immunotherapeutics

Latest From OSE Immunotherapeutics

Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE

Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.

Deal Watch Business Strategies

Alexion On Its AstraZeneca Integration And Growth Plan

Two years after being acquired by AstraZeneca, the company remains relatively autonomous in rare disease, but with “bridges” to its big pharma parent.

Rare Diseases Business Strategies

Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus

The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.

Companies Strategy

OSE On The Up As Phase III For Cancer Vaccine Is Prepped

OSE’s late-stage ambitions for Tedopi were stalled by the pandemic but the Nantes-based firm has now requested a meeting with the US FDA to get the Phase III program for the anticancer vaccine back on track.

Vaccines Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Biotech Synergy
    • Effimune SA
    • Orphan Synergy Europe Pharma
    • OSE Pharma